These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 21575258)

  • 61. DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targets.
    Wu Q; Lothe RA; Ahlquist T; Silins I; Tropé CG; Micci F; Nesland JM; Suo Z; Lind GE
    Mol Cancer; 2007 Jul; 6():45. PubMed ID: 17623056
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Association of MGMT promoter methylation with tumorigenesis features in patients with ovarian cancer: A systematic meta-analysis.
    Qiao B; Zhang Z; Li Y
    Mol Genet Genomic Med; 2018 Jan; 6(1):69-76. PubMed ID: 29195029
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Promoter hypermethylation profile of ovarian epithelial neoplasms.
    Makarla PB; Saboorian MH; Ashfaq R; Toyooka KO; Toyooka S; Minna JD; Gazdar AF; Schorge JO
    Clin Cancer Res; 2005 Aug; 11(15):5365-9. PubMed ID: 16061849
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Mechanisms of inactivation of the p16INK4a gene in leiomyosarcoma of soft tissue: decreased p16 expression correlates with promoter methylation and poor prognosis.
    Kawaguchi K; Oda Y; Saito T; Yamamoto H; Tamiya S; Takahira T; Miyajima K; Iwamoto Y; Tsuneyoshi M
    J Pathol; 2003 Nov; 201(3):487-95. PubMed ID: 14595762
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Single CpG island methylation is not sufficient to maintain the silenced expression of CASPASE-8 apoptosis-related gene among women with epithelial ovarian cancer.
    Braga Lda C; Silva LM; Ramos AP; Piedade JB; Vidigal PV; Traiman P; da Silva Filho AL
    Biomed Pharmacother; 2014 Feb; 68(1):87-91. PubMed ID: 24412083
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Functional analysis of genes in regions commonly amplified in high-grade serous and endometrioid ovarian cancer.
    Davis SJ; Sheppard KE; Pearson RB; Campbell IG; Gorringe KL; Simpson KJ
    Clin Cancer Res; 2013 Mar; 19(6):1411-21. PubMed ID: 23362323
    [TBL] [Abstract][Full Text] [Related]  

  • 67. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.
    Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR
    Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Promoter hypermethylation along with LOH, but not mutation, contributes to inactivation of DLC-1 in nasopharyngeal carcinoma.
    Feng X; Ren C; Zhou W; Liu W; Zeng L; Li G; Wang L; Li M; Zhu B; Yao K; Jiang X
    Mol Carcinog; 2014 Nov; 53(11):858-70. PubMed ID: 23908159
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Molecular genetic alterations in endometrioid carcinomas of the ovary: similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas.
    Catasús L; Bussaglia E; Rodrguez I; Gallardo A; Pons C; Irving JA; Prat J
    Hum Pathol; 2004 Nov; 35(11):1360-8. PubMed ID: 15668893
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
    Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
    Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The tumour suppressor SOX11 is associated with improved survival among high grade epithelial ovarian cancers and is regulated by reversible promoter methylation.
    Sernbo S; Gustavsson E; Brennan DJ; Gallagher WM; Rexhepaj E; Rydnert F; Jirström K; Borrebaeck CA; Ek S
    BMC Cancer; 2011 Sep; 11():405. PubMed ID: 21943380
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Frequent inactivation of hSRBC in ovarian cancers by promoter CpG island hypermethylation.
    Tong SY; Ki KD; Lee JM; Kang MJ; Ha TK; Chung SI; Chi SG; Lee SK
    Acta Obstet Gynecol Scand; 2010 May; 89(5):629-35. PubMed ID: 20423276
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Chromosome 3 anomalies investigated by genome wide SNP analysis of benign, low malignant potential and low grade ovarian serous tumours.
    Birch AH; Arcand SL; Oros KK; Rahimi K; Watters AK; Provencher D; Greenwood CM; Mes-Masson AM; Tonin PN
    PLoS One; 2011; 6(12):e28250. PubMed ID: 22163003
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The gene copy number of c-MET has a significant impact on progression-free survival in Korean patients with ovarian carcinoma.
    Kim WY; Shim SH; Jung HY; Dong M; Kim SN; Lee SJ
    Hum Pathol; 2017 Jun; 64():98-105. PubMed ID: 28428108
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Loss of heterozygosity on chromosome 13q12-q14, BRCA-2 mutations and lack of BRCA-2 promoter hypermethylation in sporadic epithelial ovarian tumors.
    Gras E; Cortes J; Diez O; Alonso C; Matias-Guiu X; Baiget M; Prat J
    Cancer; 2001 Aug; 92(4):787-95. PubMed ID: 11550149
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Aberrant promoter methylation of the RASSF1A and APC genes in epithelial ovarian carcinoma development.
    Bhagat R; Chadaga S; Premalata CS; Ramesh G; Ramesh C; Pallavi VR; Krishnamoorthy L
    Cell Oncol (Dordr); 2012 Dec; 35(6):473-9. PubMed ID: 23055343
    [TBL] [Abstract][Full Text] [Related]  

  • 77. MGMT promoter methylation is a rare epigenetic change in malignant effusions.
    Brunetti M; Panagopoulos I; Micci F; Davidson B
    Cytopathology; 2020 Jan; 31(1):12-15. PubMed ID: 31808217
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Genetic and epigenetic analysis of the putative tumor suppressor km23 in primary ovarian, breast, and colorectal cancers.
    Campbell IG; Phillips WA; Choong DY
    Clin Cancer Res; 2006 Jun; 12(12):3713-5. PubMed ID: 16778097
    [TBL] [Abstract][Full Text] [Related]  

  • 79. DNA variants of DLC-1, a candidate tumor suppressor gene in human hepatocellular carcinoma.
    Park SW; Durkin ME; Thorgeirsson SS; Popescu NC
    Int J Oncol; 2003 Jul; 23(1):133-7. PubMed ID: 12792785
    [TBL] [Abstract][Full Text] [Related]  

  • 80. p16 gene alterations in human ovarian cancers: comparison between tissue and blood samples.
    Bammidi LS; Neerukonda GN; Murthy S; Kanapuram RD
    Int J Gynecol Cancer; 2012 May; 22(4):553-60. PubMed ID: 22344043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.